Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END062
MIFTS: 51

Endometrial Hyperplasia

Categories: Cancer diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Endometrial Hyperplasia

About this section

MalaCards integrated aliases for Endometrial Hyperplasia:

Name: Endometrial Hyperplasia 12 56 45 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080365
MeSH 45 D004714
Sources

Summaries for Endometrial Hyperplasia

About this section
Disease Ontology : 12 An uterine benign neoplasm that is characterized by excessive proliferation of the cells of the endometrium.

MalaCards based summary : Endometrial Hyperplasia is related to adenocarcinoma and adenomyosis. An important gene associated with Endometrial Hyperplasia is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene Expression and Circadian entrainment. The drugs Levonorgestrel and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or... more...

Sources

Related Diseases for Endometrial Hyperplasia

About this section

Diseases related to Endometrial Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.0 CTNNB1 KRAS MLH1 PTEN
2 adenomyosis 30.6 CYP19A1 ESR1 PGR
3 atypical polypoid adenomyoma 30.4 CTNNB1 MLH1
4 adenomyoma 30.3 CTNNB1 MLH1
5 endometriosis 30.0 CYP19A1 ESR1 ESR2 PGR PTEN
6 estrogen excess 29.9 CYP19A1 ESR1 ESR2 PGR
7 leiomyoma 29.9 CYP19A1 ESR1 ESR2 PGR
8 endometrial adenocarcinoma 29.8 CTNNB1 ESR1 ESR2 KRAS MLH1 PGR
9 adenoma 29.6 CTNNB1 KRAS MLH1 MSH2
10 lynch syndrome 29.2 CTNNB1 KRAS MLH1 MSH2 MSH6
11 endometrial cancer 29.1 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
12 colorectal cancer 28.2 CDK2 CTNNB1 ESR2 KRAS MLH1 MSH2
13 ovarian cancer 27.6 CTNNB1 ESR1 ESR2 KRAS MLH1 MSH2
14 breast cancer 26.8 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
15 breast duct papilloma 10.5 PGR PTEN
16 vestibular gland benign neoplasm 10.4 ESR1 PGR
17 bartholin's gland adenoma 10.4 ESR1 PGR
18 vulvar syringoma 10.4 ESR1 PGR
19 lung leiomyoma 10.4 ESR1 PGR
20 glassy cell carcinoma of the cervix 10.4 ESR1 PGR
21 vulvar benign neoplasm 10.4 ESR1 PGR
22 polycystic ovary syndrome 10.4
23 trigonitis 10.4 ESR1 PGR
24 vulvar leiomyoma 10.4 ESR1 PGR
25 predominantly cortical thymoma 10.4 ESR1 PGR
26 breast medullary carcinoma 10.4 ESR1 PGR
27 breast scirrhous carcinoma 10.4 ESR1 PGR
28 bartholin's gland benign neoplasm 10.4 ESR1 PGR
29 oncocytic breast carcinoma 10.4 ESR1 PGR
30 endometrial squamous cell carcinoma 10.4 ESR1 PGR
31 cribriform carcinoma 10.4 ESR1 PGR
32 postmenopausal atrophic vaginitis 10.4 ESR1 ESR2
33 endometrial mucinous adenocarcinoma 10.3 ESR1 PGR
34 benign metastasizing leiomyoma 10.3 CYP19A1 PGR
35 adenoid basal cell carcinoma 10.3 ESR1 PGR
36 apocrine adenocarcinoma 10.3 ESR1 PGR
37 peritoneal benign neoplasm 10.3 ESR1 PGR
38 colorectal cancer, hereditary nonpolyposis, type 7 10.3 MLH1 MSH2
39 synchronous bilateral breast carcinoma 10.3 ESR1 PGR PTEN
40 lower lip cancer 10.3 MLH1 MSH2
41 myoma 10.3 CYP19A1 ESR1 PGR
42 mammographic density 10.3 CYP19A1 ESR1 PGR
43 prostatic hypertrophy 10.3 CYP19A1 ESR1 PGR
44 reproductive organ benign neoplasm 10.3 CYP19A1 ESR1 PGR
45 deep angioma 10.3 ESR1 PGR
46 progesterone resistance 10.3 ESR1 ESR2 PGR
47 juvenile nasopharyngeal angiofibroma 10.3 CYP19A1 ESR1 PGR
48 breast fibroadenoma 10.3 CYP19A1 ESR1 PGR
49 anal fistula 10.3 MLH1 MSH2
50 gynecomastia 10.3 CYP19A1 ESR1 PGR

Graphical network of the top 20 diseases related to Endometrial Hyperplasia:



Diseases related to Endometrial Hyperplasia
Sources

Symptoms & Phenotypes for Endometrial Hyperplasia

About this section

GenomeRNAi Phenotypes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

27 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.28 KRAS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.28 CABLES1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.28 MSH2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.28 CDK2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.28 CABLES1 KRAS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.28 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.28 KRAS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 10.28 NCOR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.28 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.28 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.28 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.28 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.28 CABLES1 CDK2 KRAS MSH2 NCOR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.28 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.28 CABLES1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.28 NCOR1
17 Decreased viability in esophageal squamous lineage GR00235-A 9.81 CDK2 CTNNB1 ESR1 KRAS MLH1 NCOA1
18 Increased cell death HMECs cells GR00103-A-0 9.35 CDK2 CTNNB1 NCOA1 PGR PTEN
19 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 ESR1 ESR2 MSH2 PTEN

MGI Mouse Phenotypes related to Endometrial Hyperplasia:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.43 CABLES1 CDK2 CTNNB1 CYP19A1 ESR1 ESR2
2 cellular MP:0005384 10.42 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
3 homeostasis/metabolism MP:0005376 10.42 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
4 immune system MP:0005387 10.41 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
5 hematopoietic system MP:0005397 10.4 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
6 integument MP:0010771 10.37 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
7 behavior/neurological MP:0005386 10.36 CABLES1 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
8 growth/size/body region MP:0005378 10.32 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
9 cardiovascular system MP:0005385 10.26 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
10 mortality/aging MP:0010768 10.26 CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
11 digestive/alimentary MP:0005381 10.25 CTNNB1 CYP19A1 ESR1 ESR2 KRAS MLH1
12 embryo MP:0005380 10.24 CDK2 CTNNB1 ESR1 KRAS NCOA1 NCOA3
13 neoplasm MP:0002006 10.21 CABLES1 CDK2 CTNNB1 ESR1 ESR2 KRAS
14 liver/biliary system MP:0005370 10.19 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
15 muscle MP:0005369 10.16 CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
16 nervous system MP:0003631 10.14 CABLES1 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
17 adipose tissue MP:0005375 10.1 CYP19A1 ESR1 ESR2 NCOA3 NCOR1 PTEN
18 hearing/vestibular/ear MP:0005377 10.04 CTNNB1 CYP19A1 ESR2 KRAS NCOA3 RBP1
19 normal MP:0002873 10.02 CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
20 limbs/digits/tail MP:0005371 9.99 CTNNB1 ESR1 ESR2 KRAS PGR PTEN
21 reproductive system MP:0005389 9.97 CABLES1 CDK2 CTNNB1 CYP19A1 ESR1 ESR2
22 renal/urinary system MP:0005367 9.86 CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
23 pigmentation MP:0001186 9.72 CTNNB1 CYP19A1 KRAS PTEN RBP1
24 skeleton MP:0005390 9.61 CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
25 vision/eye MP:0005391 9.23 CDK2 CTNNB1 CYP19A1 KRAS MLH1 NCOA3
Sources

Drugs & Therapeutics for Endometrial Hyperplasia

About this section

Drugs for Endometrial Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 797-63-7, 17489-40-6 13109
2
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71-58-9
3
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Early Phase 1 28014-46-2
4
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-28-2 5757
5
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
6
Medroxyprogesterone Phase 4,Phase 3,Phase 2,Phase 1 520-85-4 10631
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
8 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Contraceptive Agents, Male Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
13 Progestins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
15 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Early Phase 1
16 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Early Phase 1
17 Estrogens Phase 4,Phase 3,Phase 2,Early Phase 1
18 Hypoglycemic Agents Phase 4,Phase 2,Early Phase 1
19 Estrogens, Conjugated (USP) Phase 4,Phase 3,Phase 2
20
Norethindrone Approved Phase 3,Phase 2,Not Applicable,Early Phase 1 68-22-4 6230
21
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
22
Bazedoxifene Approved, Investigational Phase 3 198481-32-2
23
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
24
Methyltestosterone Approved Phase 3 58-18-4 6010
25
Testosterone enanthate Approved Phase 3 315-37-7 9416
26
Testosterone Approved, Experimental, Investigational Phase 3 58-22-0, 481-30-1 10204 6013
27
Drospirenone Approved Phase 3 67392-87-4 68873
28
Megestrol acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 595-33-5 11683
29
Tamoxifen Approved Phase 3 10540-29-1 2733526
30
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
31
Sodium Citrate Approved, Investigational Phase 3 68-04-2
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
33 Deslorelin Investigational, Vet_approved Phase 2, Phase 3 57773-65-6
34 Norethindrone Acetate Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Estrogen Receptor Modulators Phase 3
36 Bone Density Conservation Agents Phase 3
37 Selective Estrogen Receptor Modulators Phase 3
38 Estrogen Antagonists Phase 3,Phase 2
39 Raloxifene Hydrochloride Phase 3
40 Estrogen Receptor Antagonists Phase 3,Phase 2
41 Anabolic Agents Phase 3
42 Testosterone 17 beta-cypionate Phase 3
43 Androgens Phase 3
44 Natriuretic Agents Phase 3
45 diuretics Phase 3
46 Diuretics, Potassium Sparing Phase 3
47 Mineralocorticoid Receptor Antagonists Phase 3
48 Mineralocorticoids Phase 3
49 Appetite Stimulants Phase 2, Phase 3
50 Central Nervous System Stimulants Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Completed NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
2 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
3 Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
5 Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women Completed NCT00242710 Phase 3 Bazedoxifene/Conjugated Estrogen;Bazedoxifene/Conjugated Estrogen;CE 0.45 mg/MPA 1.5mg
6 Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women Completed NCT00675688 Phase 3 Bazedoxifene/Conjugate Estrogens (CE);Raloxifene;Placebo
7 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women Completed NCT00467259 Phase 3 Testosterone Transdermal System;Placebo patch
8 Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis Completed NCT00808132 Phase 3 bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;bazedoxifene 20 mg;conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;Placebo
9 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis Completed NCT00431132 Phase 3 estradiol, 10 mcg
10 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
11 Endometrial Safety Study Completed NCT00522873 Phase 3 0.25mg DRSP / 0.5mg E2 (BAY86-4891);0.5mg NETA / 1.0mg E2 (Activella)
12 Evaluate Long-Term Safety and Efficacy WC3011 Completed NCT01455597 Phase 3 Estradiol Vaginal Gel
13 Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination Completed NCT00160316 Phase 3 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
14 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms Completed NCT01942668 Phase 3 Estradiol;Progesterone;Placebo
15 Heart and Estrogen-Progestin Replacement Study (HERS) Completed NCT00319566 Phase 3 Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
16 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
17 Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Recruiting NCT03241888 Phase 2, Phase 3 Megestrol Acetate
18 Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Recruiting NCT03351062 Phase 3 Tamoxifen;Toremifene
19 MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia Not yet recruiting NCT03675139 Phase 2, Phase 3 Medroxyprogesterone Acetate;Dydrogesterone 10 MG
20 Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome Terminated NCT00566644 Phase 3
21 Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006 Unknown status NCT01234818 Phase 2
22 Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Unknown status NCT00919919 Phase 2 progesterone;activella
23 The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
24 Genistein and Endometrial Hyperplasia Completed NCT00453960 Phase 2 Norethisterone Acetate
25 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate Completed NCT00483327 Phase 2 Megestrol Acetate
26 Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids Completed NCT02465814 Phase 2 Vilaprisan (BAY1002670);Vilaprisan (BAY1002670;Vilaprisan (BAY1002670;Vilaprisan (BAY1002670);Ulipristal;Ulipristal;Ulipristal
27 Soy Estrogen Alternative Study (SEA) Completed NCT00000612 Phase 2 estrogens, conjugated
28 A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women Completed NCT00152282 Phase 2 Asoprisnil/Premarin;Asoprisnil/Premarin;Asoprisnil/Premarin;Placebo and Premarin
29 Improving the Treatment for Women With Early Stage Cancer of the Uterus Recruiting NCT01686126 Phase 2 Levonorgestrel;Metformin
30 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Recruiting NCT03300557 Phase 2 Exemestane
31 Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding Recruiting NCT03176992 Phase 2 SURGICEL®
32 Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
33 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms Active, not recruiting NCT03541200 Phase 2 MT-8554
34 Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia Terminated NCT00503581 Phase 2 Megestrol Acetate
35 Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer Terminated NCT00003179 Phase 2 medroxyprogesterone
36 Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
37 Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD) Withdrawn NCT00123175 Phase 1, Phase 2
38 Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer Withdrawn NCT01943058 Phase 2 megestrol acetate
39 Irisin Hormone Levels in Endometrial Hyperplasia Unknown status NCT02903797
40 Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study Unknown status NCT02412072
41 Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia Unknown status NCT01273636
42 Transvaginal Ultrasound in Women With Abnormal Uterine Bleeding Unknown status NCT01786798 Not Applicable
43 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
44 Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women Unknown status NCT01203176 Not Applicable
45 Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women Completed NCT01499602 Not Applicable LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland;Norethisterone Acetate tablets
46 Women With Asymptomatic Endometrial Hyperplasia Completed NCT02100137
47 Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination Completed NCT03917147
48 Metformin for the Treatment of Endometrial Hyperplasia Completed NCT01685762 Early Phase 1 Metformin
49 OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer Completed NCT01961102
50 Mirena Observational Program Completed NCT00883662 Levonorgestrel (Mirena, BAY86-5028)

Search NIH Clinical Center for Endometrial Hyperplasia

Cochrane evidence based reviews: endometrial hyperplasia

Sources

Genetic Tests for Endometrial Hyperplasia

About this section
Sources

Anatomical Context for Endometrial Hyperplasia

About this section

MalaCards organs/tissues related to Endometrial Hyperplasia:

42
Uterus, Ovary, Testes, Colon, Bone, Heart, Prostate
Sources

Publications for Endometrial Hyperplasia

About this section

Articles related to Endometrial Hyperplasia:

(show top 50) (show all 773)
# Title Authors Year
1
Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer. ( 31107747 )
2019
2
Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, In Vivo and the Impact of Metformin In Vitro. ( 30745857 )
2019
3
Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. ( 30793281 )
2019
4
Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. ( 30826750 )
2019
5
Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. ( 30017893 )
2019
6
Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. ( 30347477 )
2019
7
PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy. ( 30511741 )
2019
8
Melatonin reduced endometrial hyperplasia induced by estradiol in female albino rats. ( 30657459 )
2019
9
Could E-Cadherin and CD10 Expression be Used to Differentiate Between Atypical Endometrial Hyperplasia and Endometrial Carcinoma? ( 30726192 )
2019
10
Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. ( 30779338 )
2019
11
Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities. ( 30782821 )
2019
12
Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. ( 30802329 )
2019
13
PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? ( 30803040 )
2019
14
Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. ( 30810881 )
2019
15
Predicting risk of relapse in endometrial hyperplasia. ( 30822371 )
2019
16
Atypical Endometrial Hyperplasia Diagnosed by Hysteroscopic Photodynamic Diagnosis using 5-Aminolevulinic Acid. ( 30849521 )
2019
17
Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. ( 30887764 )
2019
18
Characteristics of patients with endometrial hyperplasia under different air quality index conditions. ( 30910154 )
2019
19
PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. ( 30915635 )
2019
20
Is there any difference between endometrial hyperplasia and endometrial carcinoma in terms of expression of TRPM2 and TRPM7 ion channels? ( 30997980 )
2019
21
Prediction of Endometrial Hyperplasia and Cancer among Premenopausal Women with Abnormal Uterine Bleeding. ( 31011581 )
2019
22
Diagnostic Value of Cytology in Detecting Endometrial Hyperplasia and Endometrial and Ovarian Cancers in Patients Undergoing Hysterectomy or Salpingo-Oophorectomy. ( 31016178 )
2019
23
Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma ( 30139240 )
2018
24
PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. ( 30342311 )
2018
25
Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis. ( 30113073 )
2018
26
Maternal obesogenic diet induces endometrial hyperplasia, an early hallmark of endometrial cancer, in a diethylstilbestrol mouse model. ( 29775456 )
2018
27
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? ( 29400014 )
2018
28
Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. ( 29121428 )
2018
29
The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia. ( 28715800 )
2018
30
Endometrial Polyps and Benign Endometrial Hyperplasia Have Increased Prevalence of DNA Fragmentation Factors 40 and 45 (DFF40 and DFF45) Together With the Antiapoptotic B-Cell Lymphoma (Bcl-2) Protein Compared With Normal Human Endometria. ( 28914671 )
2018
31
Mutation analysis by whole exome sequencing of endometrial hyperplasia and carcinoma in one patient: Abnormalities of polymerase epsilon and the phosphatidylinositol-3 kinase pathway. ( 28984400 )
2018
32
Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women. ( 29133593 )
2018
33
Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins. ( 29179590 )
2018
34
Expression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: a histopathological study. ( 29560769 )
2018
35
Proliferative and apoptotic changes in the healthy canine endometrium and in cystic endometrial hyperplasia. ( 29574305 )
2018
36
Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? ( 29665453 )
2018
37
RNA sequencing reveals significant miRNAs in Atypical endometrial hyperplasia. ( 29709726 )
2018
38
Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study. ( 29715112 )
2018
39
Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia. ( 30013435 )
2018
40
Surgical management of complex atypical endometrial hyperplasia in a woman with rare genitourinary anomalies: unicornuate uterus with rudimentary horn, ipsilateral ectopic ovary and pelvic kidney. ( 30039793 )
2018
41
Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats. ( 30056375 )
2018
42
Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer. ( 30139517 )
2018
43
Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. ( 30168854 )
2018
44
Contrast enhanced ultrasound in diagnosis of endometrial carcinoma and endometrial hyperplasia. ( 30213295 )
2018
45
Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients. ( 30255125 )
2018
46
DNA Repair Gene (XPD, XRCC4, and XRCC1) Polymorphisms in Patients with Endometrial Hyperplasia: A Pilot Study. ( 30275440 )
2018
47
The Effects of Folic Acid Supplementation on Recurrence and Metabolic Status in Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 30415553 )
2018
48
Oral and intrauterine progestogens for atypical endometrial hyperplasia. ( 30521671 )
2018
49
Does surgical treatment of atypical endometrial hyperplasia require referral to a gynecologic oncologist? ( 30527944 )
2018
50
Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: A retrospective cohort study. ( 30548528 )
2018
Sources

Variations for Endometrial Hyperplasia

About this section
Sources

Expression for Endometrial Hyperplasia

About this section
Search GEO for disease gene expression data for Endometrial Hyperplasia.
Sources

Pathways for Endometrial Hyperplasia

About this section

Pathways related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Gene Expression 67
Show member pathways
 13.72 CDK2 ESR1 ESR2 MLH1 MSH2 NCOA1
2
Circadian entrainment 38
Show member pathways
 12.96 ESR1 ESR2 KRAS NCOA1 NCOA3 PGR
3
Endometrial cancer 38
Show member pathways
 12.78 CDK2 CTNNB1 KRAS MLH1 MSH2 MSH6
4
Chks in Checkpoint Regulation 65
Show member pathways
 12.63 CDK2 ESR1 ESR2 MSH2 MSH6
5
Glioma 38
Show member pathways
 12.57 CDK2 ESR1 ESR2 KRAS MSH6 NCOA3
6
Gastric cancer 38
Show member pathways
 12.52 CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
7
Prolactin Signaling Pathway 1 38
Show member pathways
 12.44 ESR1 ESR2 KRAS NCOA1 PTEN
8
DNA Damage 4
12.43 CDK2 MLH1 MSH2 MSH6
9
Pathways in cancer 38
12.42 CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
10
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.26 ESR1 ESR2 NCOA1 NCOA3 NCOR1
11
Colorectal Cancer Metastasis 65
12.13 CTNNB1 KRAS MLH1 MSH2 MSH6
12
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.13 CDK2 ESR1 NCOA1 NCOA3 NCOR1 PGR
13
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 12.07 CTNNB1 NCOA1 NCOR1 PTEN
14
FoxO signaling pathway 38
Show member pathways
 11.99 CDK2 KRAS PTEN
15
Adipogenesis 1
11.97 CTNNB1 NCOA1 NCOR1
16
Direct p53 effectors 1
11.97 MLH1 MSH2 PTEN
17
Glioblastoma Multiforme 65
11.93 CDK2 CTNNB1 KRAS PTEN
18
Signaling by ERBB4 67
Show member pathways
 11.91 ESR1 KRAS NCOR1 PGR
19
DNA Damage Response (only ATM dependent) 1
11.9 CTNNB1 KRAS PTEN
20
Thyroid hormone signaling pathway 38
11.86 CTNNB1 ESR1 KRAS NCOA1 NCOA3 NCOR1
21
Mismatch repair 1 67 38
Show member pathways
 11.83 MLH1 MSH2 MSH6
22
TGF-beta Signaling Pathways 66
11.81 ESR1 ESR2 KRAS
23
Androgen receptor signaling pathway 1
11.81 CTNNB1 NCOA1 NCOA3 NCOR1 PTEN
24
Nuclear Receptor transcription pathway 67
Show member pathways
 11.78 ESR1 ESR2 PGR
25
Retinoblastoma (RB) in Cancer 1
11.77 CDK2 MSH6 RBP1
26
Regulation of nuclear SMAD2/3 signaling 1
11.71 CDK2 ESR1 NCOA1 NCOR1
27
Platinum drug resistance 38
11.68 MLH1 MSH2 MSH6
28
Transcription Ligand-dependent activation of the ESR1/SP pathway 23
Show member pathways
 11.66 ESR1 NCOA1 NCOA3
29
DNA damage_Role of Brca1 and Brca2 in DNA repair 23
11.53 KRAS MLH1 MSH2 MSH6
30
Aryl Hydrocarbon Receptor 1
11.47 CDK2 ESR1 KRAS
31
Integrated Breast Cancer Pathway 1
11.46 CDK2 CTNNB1 CYP19A1 ESR1 KRAS MSH2
32
Integrated Cancer Pathway 1
11.44 CDK2 MSH2 MSH6 PTEN
33
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
11.24 MLH1 MSH2 MSH6
34
Ovarian Infertility Genes 1
11.16 CYP19A1 ESR2 MLH1 NCOR1 PGR
35
AHR Pathway 65
11.14 ESR1 NCOA1 NCOA3
36
Retinoic acid receptors-mediated signaling 1
11.13 NCOA1 NCOA3 RBP1
37
MNAR-PELP1 and Estrogen Receptor Interaction 65
11.09 ESR1 ESR2 KRAS
38
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 62
10.21 CYP19A1 ESR1 ESR2
Sources

GO Terms for Endometrial Hyperplasia

About this section

Cellular components related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.55 ESR1 MSH6 NCOA1 NCOA3 NCOR1
2 nucleoplasm GO:0005654 9.44 CDK2 CTNNB1 ESR1 ESR2 MLH1 MSH2
3 MutSalpha complex GO:0032301 9.26 MSH2 MSH6
4 mismatch repair complex GO:0032300 9.13 MLH1 MSH2 MSH6
5 nucleus GO:0005634 10.18 CABLES1 CDK2 CTNNB1 ESR1 ESR2 MLH1
6 cytosol GO:0005829 10.1 CABLES1 CDK2 CTNNB1 ESR1 KRAS MSH6

Biological processes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.94 CDK2 MLH1 MSH2 MSH6
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDK2 CTNNB1 ESR1 ESR2 NCOA1 NCOA3
3 response to estradiol GO:0032355 9.79 CTNNB1 ESR1 PTEN
4 intracellular estrogen receptor signaling pathway GO:0030520 9.65 ESR1 ESR2
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.65 MLH1 MSH2 MSH6
6 uterus development GO:0060065 9.64 CYP19A1 ESR1
7 androgen metabolic process GO:0008209 9.63 CYP19A1 ESR1
8 epithelial tube branching involved in lung morphogenesis GO:0060441 9.63 CTNNB1 KRAS
9 androgen receptor signaling pathway GO:0030521 9.63 CTNNB1 NCOA1 NCOA3
10 negative regulation of DNA recombination GO:0045910 9.62 MSH2 MSH6
11 determination of adult lifespan GO:0008340 9.62 MSH2 MSH6
12 regulation of synaptic transmission, GABAergic GO:0032228 9.61 KRAS PTEN
13 protein localization to chromatin GO:0071168 9.6 ESR1 MSH2
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 MLH1 MSH2
15 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.58 ESR1 NCOR1
16 positive regulation of helicase activity GO:0051096 9.58 MSH2 MSH6
17 prostate gland growth GO:0060736 9.57 CYP19A1 PTEN
18 positive regulation of DNA-binding transcription factor activity GO:0051091 9.56 CTNNB1 ESR1 ESR2 PTEN
19 transcription, DNA-templated GO:0006351 9.55 ESR1 NCOA1
20 mismatch repair GO:0006298 9.54 MLH1 MSH2 MSH6
21 maintenance of DNA repeat elements GO:0043570 9.52 MSH2 MSH6
22 positive regulation of isotype switching to IgA isotypes GO:0048298 9.51 MLH1 MSH2
23 regulation of RNA biosynthetic process GO:2001141 9.49 NCOA1 NCOA3
24 somatic hypermutation of immunoglobulin genes GO:0016446 9.33 MLH1 MSH2 MSH6
25 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.32 MLH1 MSH2
26 pyrimidine dimer repair GO:0006290 9.26 MSH6
27 replication fork arrest GO:0043111 9.24 MSH6
28 meiotic mismatch repair GO:0000710 9.13 MSH6
29 isotype switching GO:0045190 9.13 MLH1 MSH2 MSH6
30 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MLH1 MSH2 MSH6

Molecular functions related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 transcription coactivator activity GO:0003713 9.88 CTNNB1 ESR2 NCOA1 NCOA3
2 lipid binding GO:0008289 9.83 ESR1 ESR2 PGR PTEN RBP1
3 steroid hormone receptor activity GO:0003707 9.71 ESR1 ESR2 PGR
4 nuclear receptor activity GO:0004879 9.7 ESR1 ESR2 PGR
5 chromatin binding GO:0003682 9.7 CTNNB1 ESR1 MLH1 MSH2 MSH6 NCOA1
6 androgen receptor binding GO:0050681 9.67 CTNNB1 NCOA1 NCOA3
7 estrogen receptor binding GO:0030331 9.65 CTNNB1 ESR1 NCOA1
8 four-way junction DNA binding GO:0000400 9.59 MSH2 MSH6
9 MutLalpha complex binding GO:0032405 9.58 MSH2 MSH6
10 steroid binding GO:0005496 9.58 ESR1 ESR2 PGR
11 oxidized purine DNA binding GO:0032357 9.57 MSH2 MSH6
12 estrogen receptor activity GO:0030284 9.56 ESR1 ESR2
13 single thymine insertion binding GO:0032143 9.55 MSH2 MSH6
14 estrogen response element binding GO:0034056 9.51 ESR1 ESR2
15 mismatched DNA binding GO:0030983 9.5 MLH1 MSH2 MSH6
16 single guanine insertion binding GO:0032142 9.46 MSH2 MSH6
17 guanine/thymine mispair binding GO:0032137 9.43 MLH1 MSH2 MSH6
18 nuclear receptor binding GO:0016922 9.37 NCOA1 NCOA3
19 enzyme binding GO:0019899 9.28 CTNNB1 ESR1 ESR2 MLH1 MSH2 MSH6
20 nuclear hormone receptor binding GO:0035257 9.26 CTNNB1 NCOA1 NCOA3 NCOR1
21 protein binding GO:0005515 10.44 CABLES1 CDK2 CTNNB1 ESR1 ESR2 KRAS
Sources

Sources for Endometrial Hyperplasia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....